neuro16 Flashcards
genetics of parkinsons disease
mutations I the alpha synuclein, E3 ubiquitin ligase, ubiquitin carboxyterminal esterase L1, PTEN-induced putative kinase 1, and leucine-rich repeat kinase 2
pathology of PD
dopaminergic neuronal loss in the ventral tier of the substantia nigra pars compacta with accum of Lewy bodies; neuronal loss other places as well
four cardinal features of PD
tremor, rigitiy, bradykinesia, and postural instability
tremor in PD
slow (3 to 5 per sec), and most prominent when the limb is at rest; affects the distal arm more than leg; pill rolling; tremor may also affect the lips, chin and tongue
dementia in PD
about 25 percent of patient
treatment for PD
L-dopa, given with a peripheral decarboxylase inhib
why L-dopa and not dopamine
dopamine does not cross the BBB
why the peripheral decarboxylase inhib
to prevent the conversion ot L-dopa to dopamine in the periphery, which could cause n/v, and hypertension
other agents besides L-dopa used in early PD
anticholinergics, amantadine, MAO-B inhib, COMT transferase inhib
deep brain stimulation for PD
motor thalamus, the internal segment of the globus pallidus, or the subthalamic nuc; use when patients are medially refractory
progressive supranuc palsy
a parkinsonian-like disorder with supranuc ophthalmoplegia with limited vertical more than horizontal gaze; axial rigidity and neck extension; frequent falls
corticobasal ganglionic degeneration
parkinsonian-like disorder; apraxia, cortical sensory impairment, and alien-limb phenomenon; severe unilateral rigidity; stimulus-sensitive myoclonus
Diffuse Lewy body disease
parkinsonian-like; early dementia; priminent visual hallucinations, extreme sens to extrapyramidal side effects of antidopaminergic neuroleptic drugs
Vascuar parkinsonism
“Lower half” parkinsonism with rigidity in the legs and marked gait impairment; other evidence of diffuse vascular disease (corticospinal tract dysfunction, pseudobulbar palsy)
Multiple system atrophy
parkinson-like sydnrome; early and prominent features of autonomic disfunction; evidence of corticospinal tract dysfunction; cerebellar signs; stimulus-sens myoclonus vocal cord paresis
Neuroleptic malignant syndrome
muscle rigidity, fever, autonomic lability, altered level of consciousness, elevated CK, and leukocytosis; caused by drugs
Akathisia
caused by drugs; dysphoric state characterized by need to be in constant motion; inability to sit still
treatment of akathisia
anti-cholinergics and beta blockers
tardive dyskinesia
orolinguomasticatory dyskinesia (like lipsmacking) that occurs as the most common movement disorder complicating neuroleptic use (use of dopamine receptor blockers)
the propensity of a drug to cause movement disorders
is related to its D2-receptor blocking activity
most common causes of drug-induced movement disorders
antipsychotics like haloperidol
therpeutic strategies in parkinson disease
start with levodopa/decarb inhib or dopamine agonist; if no response, increase dose and consider alternative diagnoses
for tremor-predominent PD
anticholinergic or amantadine
for early morning stiffness PD
overnight controlled-release prep of L-dopa
when patient gets L-dopa induced hallucinations
decrease dose of L-dopa; can consider giving low dose atypical antipsychotic
what to do when patient has dyskinesia and PD
reduce dose of L-dopa, add or increase dose of dopamine agonist